Published in J Acquir Immune Defic Syndr on June 01, 2007
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Continuous antiretroviral therapy decreases bone mineral density. AIDS (2009) 1.96
Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab (2010) 1.80
Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy. Ageing Res Rev (2010) 1.31
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2012) 1.14
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
Relationship between abdominal fat and bone mineral density in white and African American adults. Bone (2011) 1.01
Renal transplantation in patients with HIV. Nat Rev Nephrol (2009) 0.92
Gynecologic issues in the HIV-infected woman. Infect Dis Clin North Am (2008) 0.83
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS (2013) 0.83
Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am J Clin Nutr (2011) 0.81
Menopause-associated metabolic manifestations and symptomatology in HIV infection: a brief review with research implications. J Assoc Nurses AIDS Care (2011) 0.80
Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial. AIDS (2009) 0.79
More than osteoporosis: age-specific issues in bone health. Curr Opin HIV AIDS (2016) 0.76
Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther (2017) 0.75
Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis (2011) 3.25
Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med (2007) 3.13
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr (2005) 2.63
The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J Clin Endocrinol Metab (2008) 2.11
Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med (2006) 2.11
Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2006) 1.72
Reduced bone density in HIV-infected women. AIDS (2004) 1.70
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis (2003) 1.62
Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab (2002) 1.58
Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA (2008) 1.58
Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism (2002) 1.34
Androgen deficiency and HIV infection. Clin Infect Dis (2005) 1.29
Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism (2002) 1.17
Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA (2004) 1.16
HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med (2004) 1.10
Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr (2010) 1.10
Regional body composition in adolescents with anorexia nervosa and changes with weight recovery. Am J Clin Nutr (2003) 1.09
Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab (2004) 1.09
Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab (2004) 1.08
Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol (1985) (2005) 1.08
Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS (2012) 1.04
Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS (2007) 1.03
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008) 1.03
Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr (2002) 1.02
Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol (1985) (2003) 1.02
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr (2010) 1.02
Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab (2004) 1.01
Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS (2007) 1.01
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010) 1.00
Deiodinase 2 expression is increased in dorsocervical fat of patients with HIV-associated lipohypertrophy syndrome. J Clin Endocrinol Metab (2012) 0.98
Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution. AIDS (2006) 0.97
Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study. Arch Intern Med (2004) 0.97
Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation (2009) 0.95
Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab (2005) 0.93
Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab (2003) 0.92
Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab (2004) 0.90
Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab (2005) 0.90
Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr (2003) 0.90
Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr (2008) 0.89
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS (2005) 0.89
Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight. Clin Infect Dis (2003) 0.88
Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab (2003) 0.88
Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab (2006) 0.87
Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr (2014) 0.86
Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) (2009) 0.86
Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal-weight women. J Clin Endocrinol Metab (2004) 0.85
Reduced intravertebral bone marrow fat in HIV-infected men. AIDS (2002) 0.85
A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials (2010) 0.85
Increased hot flash severity and related interference in perimenopausal human immunodeficiency virus-infected women. Menopause (2014) 0.84
Fat fractions and spectral T2 values in vertebral bone marrow in HIV- and non-HIV-infected men: a 1H spectroscopic imaging study. Magn Reson Med (2004) 0.84
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab (2002) 0.84
Acute regulation of adiponectin by free fatty acids. Metabolism (2004) 0.83
Retinol-binding protein levels are increased in association with gonadotropin levels in healthy women. Metabolism (2009) 0.82
Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab (2002) 0.82
Characterization of leptin pulse dynamics and relationship to fat mass, growth hormone, cortisol, and insulin. Am J Physiol Endocrinol Metab (2003) 0.82
Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk? Curr Opin HIV AIDS (2008) 0.82
Effects of low-dose growth hormone withdrawal in patients with HIV. JAMA (2010) 0.82
Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am J Clin Nutr (2011) 0.81
Increased FDG uptake in association with reduced extremity fat in HIV patients. Antivir Ther (2012) 0.81
Racial differences in fat distribution: the importance of intermuscular fat. Am J Clin Nutr (2005) 0.80
Alanine aminotransferase levels predict insulin resistance in HIV lipodystrophy. J Acquir Immune Defic Syndr (2003) 0.80
Neurocognitive function in HIV-infected patients with low weight and weight loss. J Acquir Immune Defic Syndr (2003) 0.80
Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab (2004) 0.79
Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial. AIDS (2009) 0.79
Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. AIDS (2016) 0.79
Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS (2007) 0.79
Use of thiazolidinediones in HIV-infected patients: what have we learned? J Infect Dis (2007) 0.78
Reciprocal changes in endogenous ghrelin and growth hormone during fasting in healthy women. Am J Physiol Endocrinol Metab (2005) 0.77
Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf) (2009) 0.76
Effects of oral contraceptives on natriuretic peptide levels in women with hypothalamic amenorrhea: a pilot study. Fertil Steril (2011) 0.75
Effects of testosterone administration on growth hormone pulse dynamics in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2004) 0.75
Effect of estrogen receptors (reports from the FDA, NIH, ACOG, and NAMS) and the role of testosterone and bone density. J Acquir Immune Defic Syndr (2005) 0.75
Increased adrenal androgen secretion with inhibition of 11beta-hydroxylase in HIV-infected women. Am J Physiol Endocrinol Metab (2005) 0.75
Androgen deficiency and the role of testosterone administration in HIV-infected women. J Acquir Immune Defic Syndr (2005) 0.75
Strategies to augment growth-hormone secretion in obesity. Nat Clin Pract Endocrinol Metab (2009) 0.75
Physiologic effects of GHRH in patients with HIV lipodystrophy: a model of acquired visceral adiposity. Nat Clin Pract Endocrinol Metab (2006) 0.75